

2024 Annual Report and Notice of Annual General Meeting

Hong Kong, Shanghai, & Florham Park, NJ - Monday, April 7, 2025: HUTCHMED (China) Limited ("[HUTCHMED](#)") (Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2024 Annual Report, together with the Notice of Annual General Meeting and the Form of Proxy ("AGM Materials"), will be posted on April 8, 2025 to those shareholders who have elected to receive the AGM Materials in printed form. The documents can also be accessed from the HUTCHMED website (www.hutch-med.com).

The 2025 Annual General Meeting ("AGM") will be an electronic/hybrid meeting to be held at 1st Floor, Harbour Grand Kowloon, 20 Tak Fung Street, Hung Hom, Kowloon, Hong Kong on Tuesday, May 13, 2025 at 4:00 pm Hong Kong Time (9:00 am London Time), with online access through an online platform as detailed in the AGM Materials.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception, HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on [LinkedIn](#).

CONTACTS

Investor Enquiries

+852 2121 8200 / ir@hutch-med.com

Media Enquiries

FTI Consulting -

+44 20 3727 1030 / HUTCHMED@fticonsulting.com

Ben Atwell / Alex Shaw

+44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)

Brunswick - Zhou Yi

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

Panmure Liberum

Nominated Advisor and Joint Broker

Atholl Tweedie / Freddy Crossley / Rupert Dearden

+44 20 7886 2500

HSBC

Joint Broker

Simon Alexander / Alina Vaskina / Arnav Kapoor

+44 20 7991 8888

Cavendish

Joint Broker

Geoff Nash / Nigel Birks

+44 20 7220 0500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

